Cargando…
Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors
To target oncolytic measles viruses (MV) to tumors, we exploit the binding specificity of designed ankyrin repeat proteins (DARPins). These DARPin-MVs have high tumor selectivity while maintaining excellent oncolytic potency. Stability, small size, and efficacy of DARPins allowed the generation of M...
Autores principales: | Hanauer, Jan RH, Gottschlich, Lisa, Riehl, Dennis, Rusch, Tillmann, Koch, Vivian, Friedrich, Katrin, Hutzler, Stefan, Prüfer, Steffen, Friedel, Thorsten, Hanschmann, Kay-Martin, Münch, Robert C, Jost, Christian, Plückthun, Andreas, Cichutek, Klaus, Buchholz, Christian J, Mühlebach, Michael D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824561/ https://www.ncbi.nlm.nih.gov/pubmed/27119117 http://dx.doi.org/10.1038/mto.2016.3 |
Ejemplares similares
-
Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model
por: Bodmer, Bianca S., et al.
Publicado: (2018) -
Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective
por: Kleinlützum, Dina, et al.
Publicado: (2017) -
Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors
por: Wei, Min, et al.
Publicado: (2022) -
Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles
por: Hutzler, Stefan, et al.
Publicado: (2017) -
Alles neu macht das Jahr 2021: Der berufspolitische Jahresrückblick
por: Riehl, Anna
Publicado: (2021)